PAMS
ALLO icon

Pictet Asset Management (Switzerland)’s Allogene Therapeutics ALLO Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$52.1K Hold
10,480
– – ﹤0.01% 1932
2023
Q1 		$51.8K Hold
10,480
– – ﹤0.01% 1940
2022
Q4 		$66K Buy
+10,480
New +$97K ﹤0.01% 1942

Other funds holding ALLO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Pictet Asset Management (Switzerland)'s ALLO Position: Q2 2023 in Review

Pictet Asset Management (Switzerland) held its Allogene Therapeutics (ALLO) position steady in Q2 2023 at 10,480 shares worth $52.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1932.

Pictet Asset Management (Switzerland) first reported a position in ALLO in Q4 2022 and has held it in 3 quarters since. The position peaked at $66K in Q4 2022. 171 funds tracked by Wall St. Rank hold ALLO as of Q2 2023.

  • Pictet Asset Management (Switzerland) held 10,480 shares of Allogene Therapeutics worth $52.1K as of Q2 2023.
  • Pictet Asset Management (Switzerland) left its Allogene Therapeutics share count unchanged in Q2 2023.
  • Allogene Therapeutics made up ﹤0.01% of Pictet Asset Management (Switzerland)'s portfolio in Q2 2023, its #1932 holding.
  • Pictet Asset Management (Switzerland) first reported a position in Allogene Therapeutics in Q4 2022 and has held it in 3 quarters since.
  • Pictet Asset Management (Switzerland)'s Allogene Therapeutics position peaked at $66K in Q4 2022.
  • 171 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2023.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 10 Aug 2023.